Scholarlink

Objectives <p>To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT).</p> Methods <p>In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1–D5; 42/group). Groups D1–D5 received dexmedetomidine (0.2–1.0&#xa0;μg/kg) 10&#xa0;min pre-anesthesia, while controls received saline. Hemodynamic parameters heart rate (HR), mean arterial pressure (MAP), seizure duration, propofol requirements, recovery times, and adverse events were analyzed.</p> Results <p>Doses ≥ 0.4&#xa0;μg/kg (D2–D5) significantly reduced HR and MAP versus control (<i>P</i> &lt; <i>0.05</i>), with prolonged recovery in D4–D5 (<i>P</i> &lt; <i>0.05</i>). Seizure duration remained unchanged across groups. Propofol use decreased dose-dependently (D2–D5, <i>P</i> &lt; <i>0.05</i>). The D2 group (0.4&#xa0;μg/kg) achieved optimal hemodynamic stability without excessive recovery delays.</p> Conclusions <p>Dexmedetomidine pretreatment at 0.4&#xa0;μg/kg optimizes MECT anesthesia by balancing hemodynamic control, reduced propofol use, and rapid recovery, establishing it as the recommended dose.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月4日

查看全文
  • Jun Shen,
  • Min Zhou,
  • Guangliang Zhu,
  • Yu Zhang,
  • Jinzhi Ma,
  • Dekui Li,
  • Lei Chen,
  • Kejun Qi,
  • Anjiang Wang,
  • Yang Jiang,
  • Zhiming Dai,
  • Xiaoming Li

摘要

Objectives

To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT).

Methods

In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1–D5; 42/group). Groups D1–D5 received dexmedetomidine (0.2–1.0 μg/kg) 10 min pre-anesthesia, while controls received saline. Hemodynamic parameters heart rate (HR), mean arterial pressure (MAP), seizure duration, propofol requirements, recovery times, and adverse events were analyzed.

Results

Doses ≥ 0.4 μg/kg (D2–D5) significantly reduced HR and MAP versus control (P < 0.05), with prolonged recovery in D4–D5 (P < 0.05). Seizure duration remained unchanged across groups. Propofol use decreased dose-dependently (D2–D5, P < 0.05). The D2 group (0.4 μg/kg) achieved optimal hemodynamic stability without excessive recovery delays.

Conclusions

Dexmedetomidine pretreatment at 0.4 μg/kg optimizes MECT anesthesia by balancing hemodynamic control, reduced propofol use, and rapid recovery, establishing it as the recommended dose.